A Review of Turmeric (Curcuma longa) and Chicory (Cichorium intybus) in Metabolic and Hepatic Health

Abstract

Metabolic syndrome and progressive hepatic dysfunctions—which can include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), chemical hepatotoxicity, and dyslipidemia—have become a major global healthcare challenge caused by systemic low-grade inflammation and oxidative stress. Conventional pharmacological approach frequently face limitations regarding long-term tolerability, variable efficacy, and side-effect profiles, encouraged renewed scientific investigation into bioactive botanical therapeutics. Curcuma longa (Turmeric, family Zingiberaceae) and Cichorium intybus (Chicory, family Asteraceae) represent two historically prominent medicinal plants documented extensively in traditional Ayurvedic, Unani, and Chinese medical systems. This review synthesizes comparative biochemical profiles, molecular mechanisms, and pharmacological evidence supporting the therapeutic utility of C. longa (primarily via curcuminoids) and C. intybus (via inulin, sesquiterpene lactones, and polyphenols) in metabolic and hepatic homeostasis. Curcumin effectively attenuates pro-inflammatory signaling (NF-κB, TNF-α, IL-1β, COX-2), promotes phase II antioxidant enzyme transcription via the Nrf2 axis, suppresses hepatic lipid accumulation, and mitigates serum transaminases (AST, ALT) and alkaline phosphatase (ALP). Concurrently, C. intybus acts as a potent hepatoprotective and cholagogic agent, replenishing endogenous glutathione pools, counteracting lipid peroxidation, and exerting prebiotic glycemic and lipid-lowering controls through inulin-mediated microbial modulation and hepatic lipogenesis downregulation. Furthermore, the review delineates pharmacokinetics, bioavailability hurdles, toxicity considerations, and the scientific rationale for future synergistic combination strategies of both botanical agents.